BACKGROUND: Cytogenetics and multicolor flow cytometry (MFC) are useful tools for monitoring outcome of treatment in acute myeloid leukemia (AML). However, no data are available regarding the meaning of results when the 2 tests do not agree. METHODS: The authors of this report analyzed 1464 pairs of concurrent cytogenetics and flow results from 424 patients, before and after hematopoietic cell transplantation, and compared the prognostic impact of discordant and concordant results. RESULTS: Informative discordant results were observed in 22% of patients. Compared with patients who had double-negative test results, either positive result had a significant impact on overall survival and relapse-free survival. The hazard ratios with either positive cytogenetic results or positive MFC results pretransplantation were 3.1 (P = .009) and 2.5 (P = .0008), respectively, for reduced overall survival and 2.7 (P = .01) and 4.1 (P < .0001), respectively, for decreased recurrence-free survival. Similar findings were obtained post-transplantation. Molecular cytogenetics, ie, fluorescence in situ hybridization (FISH), added value to the evaluation of discordant cases. CONCLUSIONS: The detection of residual AML by either cytogenetics or flow cytometry in patients who underwent hematopoietic cell transplantation predicted early relapse and shortened survival.
BACKGROUND: Cytogenetics and multicolor flow cytometry (MFC) are useful tools for monitoring outcome of treatment in acute myeloid leukemia (AML). However, no data are available regarding the meaning of results when the 2 tests do not agree. METHODS: The authors of this report analyzed 1464 pairs of concurrent cytogenetics and flow results from 424 patients, before and after hematopoietic cell transplantation, and compared the prognostic impact of discordant and concordant results. RESULTS: Informative discordant results were observed in 22% of patients. Compared with patients who had double-negative test results, either positive result had a significant impact on overall survival and relapse-free survival. The hazard ratios with either positive cytogenetic results or positive MFC results pretransplantation were 3.1 (P = .009) and 2.5 (P = .0008), respectively, for reduced overall survival and 2.7 (P = .01) and 4.1 (P < .0001), respectively, for decreased recurrence-free survival. Similar findings were obtained post-transplantation. Molecular cytogenetics, ie, fluorescence in situ hybridization (FISH), added value to the evaluation of discordant cases. CONCLUSIONS: The detection of residual AML by either cytogenetics or flow cytometry in patients who underwent hematopoietic cell transplantation predicted early relapse and shortened survival.
Authors: Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: J P Radich; G Gehly; T Gooley; E Bryant; R A Clift; S Collins; S Edmands; J Kirk; A Lee; P Kessler Journal: Blood Date: 1995-05-01 Impact factor: 22.113
Authors: D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: T Miyamoto; K Nagafuji; K Akashi; M Harada; T Kyo; T Akashi; K Takenaka; S Mizuno; H Gondo; T Okamura; H Dohy; Y Niho Journal: Blood Date: 1996-06-01 Impact factor: 22.113
Authors: Aude G Chapuis; Daniel N Egan; Merav Bar; Thomas M Schmitt; Megan S McAfee; Kelly G Paulson; Valentin Voillet; Raphael Gottardo; Gunnar B Ragnarsson; Marie Bleakley; Cecilia C Yeung; Petri Muhlhauser; Hieu N Nguyen; Lara A Kropp; Luca Castelli; Felecia Wagener; Daniel Hunter; Marcus Lindberg; Kristen Cohen; Aaron Seese; M Juliana McElrath; Natalie Duerkopp; Ted A Gooley; Philip D Greenberg Journal: Nat Med Date: 2019-06-24 Impact factor: 53.440
Authors: A Rashidi; M A Linden; M-E Percival; B M Sandmaier; S Devine; D J Weisdorf Journal: Bone Marrow Transplant Date: 2017-10-30 Impact factor: 5.483
Authors: Miranda C Lahman; Thomas M Schmitt; Kelly G Paulson; Nathalie Vigneron; Denise Buenrostro; Felecia D Wagener; Valentin Voillet; Lauren Martin; Raphael Gottardo; Jason Bielas; Julie M McElrath; Derek L Stirewalt; Era L Pogosova-Agadjanyan; Cecilia C Yeung; Robert H Pierce; Daniel N Egan; Merav Bar; Paul C Hendrie; Sinéad Kinsella; Aesha Vakil; Jonah Butler; Mary Chaffee; Jonathan Linton; Megan S McAfee; Daniel S Hunter; Marie Bleakley; Anthony Rongvaux; Benoit J Van den Eynde; Aude G Chapuis; Philip D Greenberg Journal: Sci Transl Med Date: 2022-02-09 Impact factor: 19.319
Authors: Moreno Festuccia; H Joachim Deeg; Theodore A Gooley; Kelsey Baker; Brent L Wood; Min Fang; Brenda M Sandmaier; Bart L Scott Journal: Biol Blood Marrow Transplant Date: 2016-04-06 Impact factor: 5.742
Authors: Y Zhou; M Othus; D Araki; B L Wood; J P Radich; A B Halpern; M Mielcarek; E H Estey; F R Appelbaum; R B Walter Journal: Leukemia Date: 2016-02-29 Impact factor: 11.528
Authors: R B Walter; B Gyurkocza; B E Storer; C D Godwin; J M Pagel; S A Buckley; M L Sorror; B L Wood; R Storb; F R Appelbaum; B M Sandmaier Journal: Leukemia Date: 2014-06-03 Impact factor: 11.528
Authors: Cecilia C S Yeung; Scott McElhone; Xue Yan Chen; David Ng; Barry E Storer; H Joachim Deeg; Min Fang Journal: Mod Pathol Date: 2017-12-15 Impact factor: 7.842